

Table 1 Correlation of TACE and no TACE with clinicopathological parameters

Characteristics	Treatment		P-value
	Control	TACE	
Gender			
Female	13	8	0.505
Male	113	97	
Age (years)			
≤ 50	66	59	0.563
> 50	60	46	
AFP (ng/ml)			
≤ 400	73	55	0.398
> 400	53	50	
HBsAg			
Negative	12	5	0.168
Positive	114	100	
GGT (U/l)			
≤ 50	65	32	0.001
> 50	61	73	
Liver cirrhosis			
No	30	22	0.605
Yes	96	83	
Tumor size (cm)			
≤ 5	65	37	0.013
> 5	61	68	
Tumor number *			
Single	104	52	< 0.001
Multiple	22	53	
Tumor capsule			
No/incomplete	82	78	0.131
Complete	44	27	
Tumor differentiation			
I-II	83	63	0.357
III-IV	43	42	
Vascular invasion			
No	109	71	0.001
Yes	17	34	
TNM stage			
I	85	29	< 0.001
II	8	20	
III	33	56	
BCLC stage			
0/A	57	20	< 0.001
B/C	69	85	

*Tumor number indicates number of primary tumor mass detected at the time of surgical operation.

Table 2. Univariate and multivariate analysis of prognosis in VETC- HCC patients

Variables	TTR				OS			
	Univariate	Multivariate			Univariate	Multivariate		
	<i>P</i> -value	<i>P</i> -value	HR	95% CI	<i>P</i> -value	<i>P</i> -value	HR	95% CI
Gender (Female vs. Male)	NS	NS			NS	NS		
Age, years (≤ 50 vs. > 50)	NS	NS			NS	NS		
AFP (ng/mL) (≤ 400 vs. > 400)	< 0.001	0.002	2.223	1.336-3.698	0.001	0.003	2.369	1.335-4.204
HBsAg (Negative vs. Positive)	NS	NS			NS	NS		
GGT (U/l) (≤ 50 vs. > 50)	0.029	NS			0.022	NS		
Liver cirrhosis (No vs. Yes)	0.011	0.013	2.275	1.186-4.364	0.006	0.004	3.310	1.472-7.442
Tumor size (cm) (≤ 5 vs. > 5)	0.001	NS			< 0.001	NS		
Tumor number (Single vs. Multiple)	0.001	0.008	2.309	1.248-4.271	0.015	NS		
Tumor capsule (No/incomplete vs. Complete)	NS	NS			NS	NS		
Satellite nodule (No vs. Yes)	0.004	NS			0.003	NS		
Tumor differentiation (I-II vs. III-IV)	NS	NS			NS	NS		
Vascular invasion (No vs. Yes)	NS	NS			0.011	NS		
Adjuvant TACE (No vs. Yes)	NS	NS			NS	NS		

TTR time to recurrence, GGT gamma-glutamyltransferase, AFP α -fetoprotein, TACE transcatheter arterial chemoembolization, NS not significant, HR hazard ratio, CI confidential interval.

Table 3. Univariate and multivariate analysis of prognosis in VETC+ HCC patients

Variables	TTR				OS			
	Univariate	Multivariate			Univariate	Multivariate		
	<i>P</i> -value	<i>P</i> -value	HR	95% CI	<i>P</i> -value	<i>P</i> -value	HR	95% CI
Gender (Female vs. Male)	NS	NS			NS	NS		
Age, years (≤ 50 vs. > 50)	NS	NS			0.024	0.028	1.842	1.069-3.171
AFP (ng/mL) (≤ 400 vs. > 400)	NS	NS			NS	NS		
HBsAg (Negative vs. Positive)	NS	NS			NS	NS		
GGT (U/l) (≤ 50 vs. > 50)	NS	NS			NS	NS		
Liver cirrhosis (No vs. Yes)	NS	NS			NS	NS		
Tumor size (cm) (≤ 5 vs. > 5)	0.013	0.020	1.981	1.112-3.528	0.002	0.004	2.684	1.371-5.254
Tumor number (Single vs. Multiple)	0.002	0.002	2.713	1.448-5.083	< 0.001	< 0.001	4.931	2.401-10.129
Tumor capsule (No/incomplete vs. Complete)	NS				NS			
Satellite nodule (No vs. Yes)	0.026	NS			0.008	NS		
Tumor differentiation (I-II vs. III-IV)	NS	NS			NS	NS		
Vascular invasion (No vs. Yes)	0.001	0.002	2.305	1.345-3.950	0.003	0.003	2.444	1.352-4.419
Adjuvant TACE (No vs. Yes)	0.008	< 0.001	0.284	0.163-0.493	0.005	< 0.001	0.187	0.096-0.364

TTR time to recurrence, GGT gamma-glutamyltransferase, AFP α -fetoprotein, TACE transcatheter arterial chemoembolization, NS not significant, HR hazard ratio, CI confidential interval.